SEARCH

SEARCH BY CITATION

References

  • Bauriedel G, Jabs A, Kraemer S, Nickenig G, Skowasch D (2008). Neointimal expression of rapamycin receptor FK506-binding protein FKBP12: post-injury animal and human in-stent restenosis tissue characteristics. J Vasc Res 45: 173178.
  • Braunersreuther V, Mach F, Steffens S (2007). The specific role of chemokines in atherosclerosis. Thromb Haemost 97: 714721.
  • Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V (2004). Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein E-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 172: 3138.
  • Chinnici C, Yao Y, Praticò D (2007). The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging 28: 14571462.
  • Cizek SM, Bedri S, Talusan P, Silva N, Lee H, Stone JR (2007). Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia. Cardiovasc Pathol 16: 344350.
  • Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Praticò D (2002). Effect of low-doses aspirin on vascular inflammation, plaque stability, and atherogenesis in low density lipoprotein receptor deficient mice. Circulation 106: 1821287.
  • Cyrus T, Yao Y, Tung L, Praticò D (2006). Regression of established atherosclerosis in low density lipoprotein deficient mice by low-dose aspirin. Atherosclerosis 184: 814.
  • Cyrus T, Yao Y, Ding T, Dogne JM, Praticò D (2007). A novel thromboxane receptor antagonist and synthase inhibitor, BM573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol 561: 105111.
  • Degertekin M, Regar E, Tanabe K, Lee CH, Serruys PW (2002). Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease. Minerva Cardioangiol 50: 405418.
  • Dogne JM, Hanson J, Praticò D (2005). Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 26: 639644.
  • Elloso MM, Azrolan N, Sehgal SN, Hsu P, Ohiel KL, Kopec CA et al. (2003). Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in Apo E-deficient mice. Am J Transpl 3: 562569.
  • Farb A, John M, Acamapado E, Kolodgie FD, Prescott MF, Virmani R (2002). Oral everolimus inhibits in-stent neointimal growth. Circulation 106: 23792389.
  • Gall R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S et al. (1999). Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99: 21642170.
  • Greaves DR, Channon KM (2002). Inflammation and immune responses in atherosclerosis. Trends Immunol 23: 535541.
  • Hansson GK, Libby P, Schonbeck U, Yan ZQ (2003). Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 92: 281291.
  • Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS et al. (2001). Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Transplantation 72: 12441250.
  • Johnson JL (2007). Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 5: 265282.
  • Libby P (2002). Inflammation in atherosclerosis. Nature 420: 868874.
  • Ma KL, Ruan XZ, Powis SH, Moorhead JF, Vargese Z (2007). Anti-atherosclerotic effect of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 292: H2721H2728.
  • Marks AR (2003). Rapamycin: signaling in vascular smooth muscle. Transplant Proc 35: 231S233S.
  • Martin KA, Rzucidlo EM, Merenick BL, Fingar DC, Brown JD, Wagner RJ et al. (2004). The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 286: 507517.
  • Morales JM (2005). Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. Kidney Int 67: S69S73.
  • Morris RE, Cao W, Huang X, Gregory CR, Billingham ME, Rowan R et al. (1995). Rapamycicn (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allograft and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc 27: 430431.
  • Morriset JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ et al. (2002). Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43: 11701180.
  • Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC (2005). Effects of rapamycicn on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transpl Proc 37: 18801884.
  • Oude Nijhuis MM, Van Keulen JK, Pasterkamp G, Quax PH, De Kleijn DP (2007). Activation of the innate immune system in atherosclerotic disease. Curr Pharm Des 13: 983994.
  • Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR (2005). Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98: 22772283.
  • Praticò D, Dogne J-M. (2005). Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation 112: 10731079.
  • Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM (1994). Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 14: 122.
  • Snell GI, Levvey BJ, Chin W, Kotsimbos T, Whitford H, Waters KN et al. (2003). Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 21: 540546.
  • Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. (2001). Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimentional intravascular ultrasound study. Circulation 103: 192195.
  • Tedgui A, Mallat Z (2006). Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515581.
  • Verheye S, Martinet W, Kockx MM, Knaapen MWM, Salu K, Timmermans JP et al. (2007). Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 49: 706715.
  • Zohlnhofer D, Klein CA, Richter T, Brandl R, Murr A, Nuhrenberg T et al. (2001). Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy. Detection of FK506-binding protein 12 upregulation. Circulation 103: 13961402.